Form 4: Palisade Bio CEO John David Finley Buys 1,000 Shares of Common Stock
SEC Form 4 Filing
Palisade Bio's CEO, John David Finley, recently acquired 1,000 shares of the company's common stock at $4.81 per share.
Summary
- On May 24, 2024, John David Finley, CEO, CFO, and Director of Palisade Bio, Inc., purchased 1,000 shares of common stock at a price of $4.81 per share.
- Following this transaction, Finley directly owns 8,437 shares of Palisade Bio's common stock.
- Finley also indirectly owns 51 shares through FCW Investments, LLC, where he serves as the managing member with sole investment and voting power.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but the purchase is relatively small and doesn't provide a strong indication of future performance.
Positives
- The CEO's purchase of company stock may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor among many to consider when evaluating a company's potential.
Stakeholder Impact
- The stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/24/2024 | Date of the stock purchase transaction. |
| 05/28/2024 | Date of signature on the SEC Form 4. |
Keywords
Palisade Bio, John David Finley, Insider Trading, Stock Purchase, Common Stock, PALI, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.